Sign in
Not yet taking people in PolandPhase 3

Testing CT-P13 injections for moderately to severely active rheumatoid arthritis

Tests CT-P13 injected under the skin in adults with active rheumatoid arthritis.

Key facts

Who runs it
Celltrion Inc.
Where
Bydgoszcz, Nadarzyn, Olsztyn, Plonsk, Tomaszów Lubelski, Warsaw, and Wroclaw, PolandSee the 10 sites
Registry title
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
Status
Not yet recruiting
Phase
Phase 3
People taking part
266 people, planned
Starts
1 Jan 2027
Expected to end
31 May 2028
Type of study
Interventional
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with moderately to severely active rheumatoid arthritis who already take methotrexate.

Age
18 to 75 years old (both inclusive)
Sex
Men and women can join
Disease stage
Rheumatoid arthritis diagnosed at least 24 weeks before the first dose, with active disease: 6 or more swollen joints and 6 or more tender joints, plus raised CRP or ESR.
Earlier treatment
Must have taken methotrexate for at least 24 weeks, on a stable dose of 10 to 25 mg/week for at least 8 weeks. Must not have taken infliximab or targeted synthetic DMARDs such as tofacitinib or baricitinib.
Biomarker or test result
At least one of: positive anti-CCP, positive rheumatoid factor (RF), or, if both are negative, at least 1 bone erosion on X-ray.

Main reasons for not taking part

  • Has taken infliximab before
  • Has taken more than 2 biologic DMARDs for rheumatoid arthritis
  • Did not respond well to a TNF alpha inhibitor
  • Has taken a B-cell depleting drug such as rituximab
  • Allergy to infliximab ingredients, murine or human proteins, or immunoglobulin products

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patient who is male or female aged 18 to 75 years old (both inclusive)
  • Patient who has a diagnosis of RA at least 24 weeks prior to the first administration of the study drug (Day 1) and fulfill the 2010 ACR/EULAR classification criteria for RA
  • Patient who has active disease as defined by the presence of 6 or more swollen joints (of 66 assessed), 6 or more tender joints (of 68 assessed) at Screening and baseline, and either a C-reactive protein (CRP) ≥1.0 mg/dL (≥10 mg/L) (at Screening) or an erythrocyte sedimentation rate (ESR) ≥28 mm/hour (at Screening and baseline)
  • Patient who has at least one of the following at Screening: a) Positive for anti-cyclic citrullinated peptide (anti-CCP); or b) Positive for rheumatoid factor (RF); or c) If both RF and anti-CCP are negative, ≥1 bone erosions of the joints on X-ray on locally read screening X-ray
  • Patient who has been receiving the treatment of oral or parenteral dosing with MTX for at least 24 weeks and has been on stable dosing with MTX between 10 to 25 mg/week for at least 8 weeks prior to the first administration of the study drug (Day 1)

Who cannot take part

  • Patients who have previously received infliximab, for any purpose, cannot be enrolled
  • Patient who has previously received investigational or licensed biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of RA, who meets any of following conditions a) Patient who has previously received more than 2 investigational or licensed bDMARDs for the treatment of RA, b) Patients with history of inadequate response to tumor necrosis factor (TNF) α inhibitor (the reason for discontinuation due to lack of efficacy), c) Patients who have received a B-cell depleting agent (e.g., rituximab) for the treatment of RA, d) Patients who have not met the required washout period prior to the first administration of study drug for the bDMARD specified below, or at least five times the mean terminal elimination half-life of the drug if not specified: • ≥ 4 weeks for etanercept; • ≥ 8 weeks for adalimumab, certolizumab, golimumab, abatacept, sarilumab and tocilizumab
  • Patient who has previously received any investigational or licensed targeted synthetic DMARDs (e.g., tofacitinib, baricitinib) for the treatment of RA
  • Patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product

Where in Poland

  • ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. SupronikPolandNot yet recruiting
  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandNot yet recruiting
  • NZOZ Lecznica MAK MED S CNadarzyn, PolandNot yet recruiting
  • Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.Olsztyn, PolandNot yet recruiting
  • Innova Clinic Sp. z o.o.Plonsk, PolandNot yet recruiting
  • Samodzielny Publiczny Zespol Opieki Zdrowotnej W Tomaszowie LubelskimTomaszów Lubelski, PolandNot yet recruiting
  • Klinika Reuma Park Sp. z o.o. S.K.Warsaw, PolandNot yet recruiting
  • Medicover Integrated Clinical Services Sp. z o.o.Warsaw, PolandNot yet recruiting
  • Rheuma Medicus Sp z o oWarsaw, PolandNot yet recruiting
  • Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.oWroclaw, PolandNot yet recruiting

About the trial

What the trial wants to find out

To demonstrate superiority of CT-P13 SC over Placebo in terms of efficacy as determined by clinical response according to the American College of Rheumatology (ACR) definition of a 50% improvement (ACR50) at Week 12.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
Plain-language title
Testing CT-P13 injections for moderately to severely active rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 October 2026